ArticleLancet (London, England)2003
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Article in Lancet (London, England), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00338260 (A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.Journal of human hypertension · 2004Guideline
- Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.Journal of human hypertension · 2007Trial
- Atrial Electrical Remodeling in Mice With Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor.Journal of the American Heart Association · 2022Article
- Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?Journal of human hypertension · 2020Review
- Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks".Journal of clinical hypertension (Greenwich, Conn.) · 2018Review
- Different protein kinase C isoenzymes mediate inhibition of cardiac rapidly activating delayed rectifier KBritish journal of pharmacology · 2017Article
- Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).European heart journal. Cardiovascular pharmacotherapy · 2017Review
- Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment.Clinical pharmacokinetics · 2013Article
- Value of Angiotensin receptor blocker therapy in diabetes.Journal of clinical hypertension (Greenwich, Conn.) · 2011Review
- Redox regulation, NF-kappaB, and atrial fibrillation.Antioxidants & redox signaling · 2009Review
- Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.British journal of pharmacology · 2008Article
- The effect of angiotensin receptor blockers for preventing atrial fibrillation.Current hypertension reports · 2007Review
- Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation.American journal of physiology. Heart and circulatory physiology · 2007Article
- Implantable cardioverter defibrillators for prevention of sudden cardiac death.Clinical cardiology · 2007Review
- Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation.Current cardiology reports · 2006Review
- Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.PharmacoEconomics · 2006Review
- Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?Journal of human hypertension · 2005Review
- Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death.Journal of general internal medicine · 2005Article
- Left ventricular hypertrophy in hypertension: its arrhythmogenic potential.Heart (British Cardiac Society) · 2005Review
- Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0.027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.